However, HDAC inhibitors have had limited clinical success in the treatment of glioblastoma due to their high toxicity and low specificity, with valproic acid being the only HDAC inhibitor that has advanced to a phase III clinical trial (NCT03243461) [14]. Here, HDAC9 is linked to glioblastoma.